Demonstrations showcased ex vivo epigenetic editing of CDKN2B with lasting methylation after engraftment in mice, along with mapping epigenetic pathways of macrophage activation, highlighting translational progress toward therapies.

Advances in high-throughput and computational tools include HT-recruit screening of thousands of domains, the COMBINE platform for combinatorial editing, single-cell perturbation methods, and modeling tools like SPIDER to infer regulatory networks and predict transcription factor binding events.

The conference signals a field in transition toward therapeutic epigenome engineering, balancing scientific momentum with safety, standardization, and academia‑industry collaboration.

Keynote speakers noted that distant enhancers must be brought within a proximity of 200–300 nanometers to promoters, with cohesin-mediated loop extrusion shaping enhancer action and evidence of bystander activation across domain boundaries.

Technical innovations expanded the epigenetic editing toolkit, including deeper insights into DNMTs, bioorthogonal labeling of methylation processes, and strategies to reduce editor cytotoxicity while preserving function in tools like P300.

Safety and risk discussions highlighted off-target methylation occurring days after editing, variable cell-type responses to reprogramming, and calls for standardized reporting of off-target effects, with some findings suggesting widespread unintended methylation across editors.

Epigenetic reader domains are becoming central tools, with approaches like ChromID, chimeric reader domains for spike-ins, BiAD visualization, and live-cell imaging to study epigenetic marks in real time.

Epigenetic editing is moving toward (pre)clinical applications, with more than ten companies pursuing therapies and an ongoing clinical trial highlighted at EpiBio-24 in Amsterdam.

A final keynote demonstrated durable epigenetic therapy in mice by simultaneously applying DNA methylation and repressive histone marks to achieve stable gene repression, including long-term PCSK9 silencing and retention of methylation after liver regrowth, suggesting durability and potential heritability in tissue contexts.